Pitavastatin: a New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor for the Treatment of Hyperlipidemia
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : William L. Baker , Rupangi Datta
- چاپ و سال / کشور: 2011
Description
Statins have proven beneficial for reducing both primary and secondary events in patients with coronary heart disease. Tight control of serum lipid parameters in these patients is recommended by the most recent clinical guidelines. Although numerous lipidlowering treatments are available, only a small percentage of eligible patients receive therapy and fewer achieve their lipid-lowering goals. Thus it is clear that new treatment strategies to manage patients with lipid abnormalities are warranted. Pitavastatin (Livalo®; Kowa Pharmaceuticals America, Montgomery, AL, USA) has been recently approved for the treatment of hypercholesterolemia and combined dyslipidemia. Pitavastatin 1-4 mg/day has shown similar low-density lipoproteinreducing activity to other commercially available statins, including simvastatin and atorvastatin. Adverse events occurred at similar rates to other statins in clinical trials with favorable DOI: 10.1007/ s12325-010- 0092-8 effects seen in patients with dyslipidemia and metabolic syndrome. Pharmacokinetic drugdrug interactions are minimized due to the lack of significant metabolism of pitavastatin by the cytochrome P450 enzyme system, although some drugs affect its uptake into hepatocytes and should be avoided. In addition to its higher acquisition cost, pitavastatin has not been shown to improve clinical outcomes in high-risk patient populations and thus may not be the agent of choice in many patients at this time in lieu of cheaper, clinically proven alternatives.
Adv Ther (2011) 28(1):13-27. DOI: 10.1007/s12325-010-0092-8 Received: October 1, 2010 / Published online: December 9, 2010
